Literature DB >> 19386594

Herpes simplex virus gD forms distinct complexes with fusion executors gB and gH/gL in part through the C-terminal profusion domain.

Tatiana Gianni1, Michele Amasio, Gabriella Campadelli-Fiume.   

Abstract

Herpes simplex virus entry into cells requires a multipartite fusion apparatus made of glycoprotein D (gD), gB, and heterodimer gH/gL. gD serves as a receptor-binding glycoprotein and trigger of fusion; its ectodomain is organized in an N-terminal domain carrying the receptor-binding sites and a C-terminal domain carrying the profusion domain, required for fusion but not receptor binding. gB and gH/gL execute fusion. To understand how the four glycoproteins cross-talk to each other, we searched for biochemical defined complexes in infected and transfected cells and in virions. Previously, interactions were detected in transfected whole cells by split green fluorescent protein complementation (Atanasiu, D., Whitbeck, J. C., Cairns, T. M., Reilly, B., Cohen, G. H., and Eisenberg, R. J. (2007) Proc. Natl. Acad. Sci. U. S. A. 104, 18718-18723; Avitabile, E., Forghieri, C., and Campadelli-Fiume, G. (2007) J. Virol. 81, 11532-11537); it was not determined whether they led to biochemical complexes. Infected cells harbor a gD-gH complex (Perez-Romero, P., Perez, A., Capul, A., Montgomery, R., and Fuller, A. O. (2005) J. Virol. 79, 4540-4544). We report that gD formed complexes with gB in the absence of gH/gL and with gH/gL in the absence of gB. Complexes with similar composition were formed in infected and transfected cells. They were also present in virions prior to entry and did not increase at virus entry into the cell. A panel of gD mutants enabled the preliminary location of part of the binding site in gD to gB to the amino acids 240-260 portion and downstream with Thr304-Pro305 as critical residues and of the binding site to gH/gL at the amino acids 260-310 portion with Pro291-Pro292 as critical residues. The results indicate that gD carries composite-independent binding sites for gB and gH/gL, both of which are partly located in the profusion domain.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19386594      PMCID: PMC2719377          DOI: 10.1074/jbc.M109.005728

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  57 in total

1.  Glycoprotein D or J delivered in trans blocks apoptosis in SK-N-SH cells induced by a herpes simplex virus 1 mutant lacking intact genes expressing both glycoproteins.

Authors:  G Zhou; V Galvan; G Campadelli-Fiume; B Roizman
Journal:  J Virol       Date:  2000-12       Impact factor: 5.103

2.  The 85-kilodalton phosphoprotein (pp85) of human herpesvirus 7 is encoded by open reading frame U14 and localizes to a tegument substructure in virion particles.

Authors:  A Stefan; P Secchiero; T Baechi; W Kempf; G Campadelli-Fiume
Journal:  J Virol       Date:  1997-08       Impact factor: 5.103

3.  The UL10 gene of herpes simplex virus 1 encodes a novel viral glycoprotein, gM, which is present in the virion and in the plasma membrane of infected cells.

Authors:  J D Baines; B Roizman
Journal:  J Virol       Date:  1993-03       Impact factor: 5.103

4.  Herpes simplex virus-1 entry into cells mediated by a novel member of the TNF/NGF receptor family.

Authors:  R I Montgomery; M S Warner; B J Lum; P G Spear
Journal:  Cell       Date:  1996-11-01       Impact factor: 41.582

5.  Development of recombinant diagnostic reagents based on pp85(U14) and p86(U11) proteins to detect the human immune response to human herpesvirus 7 infection.

Authors:  A Stefan; M De Lillo; G Frascaroli; P Secchiero; F Neipel; G Campadelli-Fiume
Journal:  J Clin Microbiol       Date:  1999-12       Impact factor: 5.948

6.  DNA vaccination against rat her-2/Neu p185 more effectively inhibits carcinogenesis than transplantable carcinomas in transgenic BALB/c mice.

Authors:  S Rovero; A Amici; E Di Carlo; R Bei; P Nanni; E Quaglino; P Porcedda; K Boggio; A Smorlesi; P L Lollini; L Landuzzi; M P Colombo; M Giovarelli; P Musiani; G Forni
Journal:  J Immunol       Date:  2000-11-01       Impact factor: 5.422

7.  Mapping of herpes simplex virus 1 genes with mutations which overcome host restrictions to infection.

Authors:  R Brandimarti; T Huang; B Roizman; G Campadelli-Fiume
Journal:  Proc Natl Acad Sci U S A       Date:  1994-06-07       Impact factor: 11.205

8.  Entry of alphaherpesviruses mediated by poliovirus receptor-related protein 1 and poliovirus receptor.

Authors:  R J Geraghty; C Krummenacher; G H Cohen; R J Eisenberg; P G Spear
Journal:  Science       Date:  1998-06-05       Impact factor: 47.728

9.  A mutant herpes simplex virus type 1 unable to express glycoprotein L cannot enter cells, and its particles lack glycoprotein H.

Authors:  C Roop; L Hutchinson; D C Johnson
Journal:  J Virol       Date:  1993-04       Impact factor: 5.103

10.  Glycoproteins gB, gD, and gHgL of herpes simplex virus type 1 are necessary and sufficient to mediate membrane fusion in a Cos cell transfection system.

Authors:  A Turner; B Bruun; T Minson; H Browne
Journal:  J Virol       Date:  1998-01       Impact factor: 5.103

View more
  64 in total

1.  Structure-based functional analyses of domains II and III of pseudorabies virus glycoprotein H.

Authors:  Sebastian W Böhm; Elisa Eckroth; Marija Backovic; Barbara G Klupp; Felix A Rey; Thomas C Mettenleiter; Walter Fuchs
Journal:  J Virol       Date:  2014-11-12       Impact factor: 5.103

2.  αVβ3-integrin relocalizes nectin1 and routes herpes simplex virus to lipid rafts.

Authors:  Tatiana Gianni; Gabriella Campadelli-Fiume
Journal:  J Virol       Date:  2011-12-14       Impact factor: 5.103

3.  Cascade of events governing cell-cell fusion induced by herpes simplex virus glycoproteins gD, gH/gL, and gB.

Authors:  Doina Atanasiu; Wan Ting Saw; Gary H Cohen; Roselyn J Eisenberg
Journal:  J Virol       Date:  2010-09-22       Impact factor: 5.103

4.  Dissociation of HSV gL from gH by αvβ6- or αvβ8-integrin promotes gH activation and virus entry.

Authors:  Tatiana Gianni; Raffaele Massaro; Gabriella Campadelli-Fiume
Journal:  Proc Natl Acad Sci U S A       Date:  2015-07-08       Impact factor: 11.205

5.  Functional hierarchy of herpes simplex virus 1 viral glycoproteins in cytoplasmic virion envelopment and egress.

Authors:  Dmitry V Chouljenko; In-Joong Kim; Vladimir N Chouljenko; Ramesh Subramanian; Jason D Walker; Konstantin G Kousoulas
Journal:  J Virol       Date:  2012-02-08       Impact factor: 5.103

6.  Fusion-deficient insertion mutants of herpes simplex virus type 1 glycoprotein B adopt the trimeric postfusion conformation.

Authors:  Jessica L Silverman; Sapna Sharma; Tina M Cairns; Ekaterina E Heldwein
Journal:  J Virol       Date:  2009-11-25       Impact factor: 5.103

7.  Capturing the herpes simplex virus core fusion complex (gB-gH/gL) in an acidic environment.

Authors:  Tina M Cairns; J Charles Whitbeck; Huan Lou; Ekaterina E Heldwein; Tirumala K Chowdary; Roselyn J Eisenberg; Gary H Cohen
Journal:  J Virol       Date:  2011-04-20       Impact factor: 5.103

8.  Herpes simplex virus glycoproteins H/L bind to cells independently of {alpha}V{beta}3 integrin and inhibit virus entry, and their constitutive expression restricts infection.

Authors:  Tatiana Gianni; Arianna Cerretani; Rebecca Dubois; Stefano Salvioli; Scott S Blystone; Felix Rey; Gabriella Campadelli-Fiume
Journal:  J Virol       Date:  2010-02-10       Impact factor: 5.103

9.  Low-pH-dependent changes in the conformation and oligomeric state of the prefusion form of herpes simplex virus glycoprotein B are separable from fusion activity.

Authors:  Stephen J Dollery; Catherine C Wright; David C Johnson; Anthony V Nicola
Journal:  J Virol       Date:  2011-08-03       Impact factor: 5.103

10.  Insertion mutations in herpes simplex virus 1 glycoprotein H reduce cell surface expression, slow the rate of cell fusion, or abrogate functions in cell fusion and viral entry.

Authors:  Julia O Jackson; Erick Lin; Patricia G Spear; Richard Longnecker
Journal:  J Virol       Date:  2009-12-09       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.